Pregnancy and the postpartum period are associated with several physiological changes
that can alter the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs. For certain …

Physiologically based pharmacokinetic (PBPK) modeling is used to predict the
pharmacokinetic behavior of xenobiotics in humans. During pregnancy, anatomical and …

Physiologically-based pharmacokinetic (PBPK) modeling has emerged as a useful tool to
study pharmacokinetics (PK) in special populations, such as pregnant women, fetuses, and …

Physiologically based pharmacokinetic (PBPK) modelling in pregnancy is a relatively new
approach that is increasingly being used to assess drug systemic exposure in pregnant …

This lecture was given by Dr. Burckart in association with presentation of the 2014 Sumner J.
Yaffe Lifetime Achievement Award in Pediatric Pharmacology and Therapeutics, which is …

The regulatory framework for considering the fetal effects of new drugs is limited. This is
partially due to the fact that pediatric regulations (21 CFR subpart D) do not apply to the …

The objective of this study was to develop a physiologically based pharmacokinetic (PBPK)
model for amoxicillin for non-pregnant, pregnant and postpartum populations by compiling a …

Abstract Background and Objective Little is understood about neonatal pharmacokinetics
immediately after delivery and during the first days of life following intrauterine exposure to …

Aims Long‐acting cabotegravir and rilpivirine have been approved to manage HIV in adults,
but data regarding safe use in pregnancy are limited. Physiologically‐based …

Little is known about placental drug transfer and fetal pharmacokinetics despite increasing
drug use in pregnant women. While physiologically based pharmacokinetic (PBPK) models …